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Abstract Ethyl-3,4-dihydroxybenzoate (EDHB) is commonly
utilized as a substrate analog and competitive inhibitor of prolyl
4-hydroxylases. These iron-dependent enzymes have received a lot
of attention for their involvement in crucial biochemical pathways
such as collagen maturation and oxygen sensing. Since EDHB is
also capable of chelating the enzyme-bound iron, we study here its
function as a chelator. We show that the a⁄nity of EDHB for
ferric iron is signi¢cantly lower than that of desferrioxamine.
Nevertheless, EDHB is su⁄cient to promote e¡ective iron de¢-
ciency in cells, re£ected in the activation of the iron-responsive
element/iron regulatory protein regulatory network. Thus, treat-
ment of B6 ¢broblasts with EDHB results in slow activation of
iron regulatory protein 1 accompanied by an increase in trans-
ferrin receptor levels and reduction of the ferritin pool.
0 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Hydroxylation of amino acid residues is emerging as an
important checkpoint in various biochemical pathways. For
example, it has been known for many years that proline hy-
droxylation is necessary for the maturation of collagen, the
major protein of connective tissue, because 4-hydroxyproline
is indispensable in the stabilization of collagen’s triple helix
[1]. More recently, it was ¢rmly established that proline hy-
droxylation is involved in a mechanism for oxygen sensing.
Cells of higher eukaryotes respond to reduced oxygen avail-
ability by activation of the hypoxia inducible factor (HIF)
that controls the transcription of a wide array of genes in-
volved in erythropoiesis, angiogenesis, cell proliferation/sur-
vival, glycolysis and iron metabolism. In mammals, these
include, among many others, erythropoietin, vascular endo-
thelial growth factor, transferrin and transferrin receptor [2].
The expression of HIF is regulated at the level of protein
stability. Under normoxic conditions, the oxygen-sensitive
subunit HIF-1K is hydroxylated at two proline residues within
two functionally independent degradation domains. This
modi¢cation provides a recognition site for the von Hippel^
Lindau tumor suppressor protein, a component of an E3
ubiquitin ligase complex. This interaction results in ubiquiti-
nation and degradation of HIF-1K by the proteasome [3,4].
The enzymes catalyzing the hydroxylation of prolines and
other amino acid residues belong to the family of 2-oxogluta-
rate-dependent oxygenases [5] and require ascorbate, iron and
oxygen as cofactors. The prolyl 4-hydroxylases that modify
HIF-1K and collagen are homologous but distinct. The former
appear to function as oxygen sensors [6,7]. It is obvious that
control of the activity of prolyl 4-hydroxylases is of profound
biomedical relevance. A screen of several hydroxybenzene and
hydroxybenzoic acid derivatives that are structurally related
to 2-oxoglutarate and ascorbate has provided a ¢rst set of
prolyl 4-hydroxylase inhibitors [8]. Among them, 3,4-dihy-
droxybenzoate displayed a strong (Ki = 5 WM) competitive in-
hibition towards 2-oxoglutarate and ascorbate. In the last
15 years, the cell-permeable ethyl ester of 3,4-dihydroxyben-
zoate (EDHB) has commonly been employed in cell culture
experiments as a speci¢c inhibitor of collagen synthesis [9^14].
As an ortho-dihydroxy derivative, 3,4-dihydroxybenzoate
also has the capacity to inhibit enzyme activity in a non-com-
petitive fashion by chelating enzyme-bound iron [8]. This no-
tion prompted us to investigate the iron chelating properties
of EDHB and its e¡ect in cellular iron metabolism.
2. Materials and methods
2.1. Cell culture and reagents
B6 murine ¢broblasts were grown in Dulbecco’s modi¢ed Eagle’s
medium (Gibco) supplemented with 2 mM glutamine, 100 U/ml pen-
icillin, 0.1 ng/ml streptomycin and 10% fetal calf serum. EDHB was
purchased from Sigma and desferrioxamine (DFO) from Novartis.
2.2. Determination of EDHB a⁄nity for Fe(III)
The conditional dissociation constant for the Fe^EDHB complex in
phosphate-bu¡ered saline was determined using a Cary 1 spectropho-
tometer, by competition with EDTA at 25‡C. Data were analyzed at
490 nm, at which the only signi¢cantly absorbing species is Fe-
(EDHB)3. Ferric iron, prepared as a 5 mM stock solution of FeCl3
in 100 mM sodium citrate, was diluted to 25 WM in the presence of
750 WM EDHB. The loss of absorbance on the addition of 25 WM
EDTA was used to calculate the equilibrium constant:
Keq ¼ ½FeðEDHBÞ3½EDTA=½FeEDTA½EDHB3 ¼
KDðEDHBÞ=KDðEDTAÞ
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2.3. Electrophoretic mobility shift assay (EMSA)
The cells were lysed in ‘cytoplasmic lysis bu¡er’ (1% Triton X-100,
40 mM KCl, 25 mM Tris^HCl, pH 7.4). Analysis of iron-responsive
element (IRE) binding by EMSA was performed as in [15].
2.4. Western blotting
Half of the cells in each sample were lysed in ‘cytoplasmic lysis
bu¡er’. Lysates containing 30 Wg of total protein were resolved by
SDS^PAGE on a 7.5% gel and the proteins were transferred onto
nitrocellulose ¢lters. The blots were saturated with 10% non-fat
milk in phosphate-bu¡ered saline and probed with 1:1000 diluted
antibodies against transferrin receptor (TfR; Zymed) and L-actin (Sig-
ma). The other half of the cells were directly lysed in Laemmli sample
bu¡er and immediately boiled for 5 min [16]. Equal aliquots of lysates
were resolved by SDS^PAGE on 11% gels and transferred onto nitro-
cellulose ¢lters. The blots were saturated as above and probed with
1:1500 diluted antibody against ferritin (Roche). Following a wash
with phosphate-bu¡ered saline containing 0.1% Tween 20, the blots
with the TfR monoclonal antibodies were incubated with peroxidase-
coupled rabbit anti-mouse IgG (1:4000 dilution). The blots with L-ac-
tin and ferritin polyclonal antibodies were incubated with peroxidase-
coupled goat anti-rabbit IgG (1:5000 dilution). Detection of peroxi-
dase-coupled antibodies was performed with the enhanced chemilumi-
nescence method (Amersham).
3. Results
To evaluate the function of EDHB as an iron chelator, we
¢rst examined its iron binding capacity in vitro. To this end,
we determined the conditional dissociation constant (KD) of
the Fe(III)^EDHB complex. It was assumed that Fe(III)^
EDHB has the 1:3 stoichiometry characteristic of small bi-
dentate ligands. The value of KD for Fe^(EDHB)3, 1.86U
10327 M3, and those of Fe^EDTA and Fe^DFO are given
in Table 1. The hexadentate ligands DFO and EDTA form
complexes with a 1:1 Fe:ligand stoichiometry. Because the
dissociation constants of bidentate and hexadentate ligands
to Fe(III) have di¡erent units, direct comparison of a⁄nities
using KD values is not simple. To make comparison possible,
the parameter ‘pM’ is used, which is the 3log of free [Fe(III)]
in the presence of 1 WM total Fe(III) and 1 mM total ligand at
pH 7.4. It can be inferred from the pM values shown in Table
1 that EDHB has approximately 40 times lower a⁄nity to
Fe(III) than EDTA, which in turn has approximately 2000
times lower a⁄nity to Fe(III) than DFO. Thus, under the
above conditions, EDHB is an iron chelator V80 000 times
weaker than DFO.
We then investigated the e¡ects of EDHB in cellular iron
metabolism and the IRE/IRP regulatory system. The expres-
sion of several proteins of iron metabolism, such as TfR and
ferritin, which mediate iron uptake and storage, respectively,
is regulated post-transcriptionally by iron regulatory proteins
(IRPs) at the levels of mRNA stability or translation. The
mechanism involves binding of IRPs to IREs within the un-
translated regions of the respective mRNAs [17,18]. To assess
the e¡ects of EDHB in the IRE/IRP system, mouse B6 ¢bro-
blasts were exposed to di¡erent doses of the drug for 12 h and
IRE binding activity was analyzed by EMSA (Fig. 1). The
concentrations of EDHB tested here (ranging from 200 to
400 WM) were previously reported to be e¡ective for the inhi-
bition of prolyl 4-hydroxylases in other experimental settings
[9,10]. Under all these conditions, EDHB leads to a profound
activation of IRP1 (lanes 1^4). The e¡ect is comparable to a
treatment with the established iron chelator DFO (lane 5). An
analysis of the same extracts for IRE binding following treat-
ment with 2-mercaptoethanol, known to activate dormant
IRP1 [17,18], con¢rms equal loading (bottom panel).
The e¡ects of EDHB on IRE binding activity were further
analyzed in a time course experiment (Fig. 2). As a control,
B6 cells were treated with 100 WM DFO for di¡erent time
intervals. A sustained treatment with DFO for s 4 h results
in the activation of IRP1 (lanes 1^7). These kinetics are in
agreement with earlier ¢ndings [19]. Importantly, a treatment
with 200 WM EDHB also leads to a complete activation of
IRP1 after 4 h, while a partial activation of IRP1 within 2^4 h
is also observed (lanes 8^14). The control analysis with 2-mer-
captoethanol is shown in the bottom panel.
We ¢nally examined the e¡ects of EDHB in the expression
of downstream IRP1 targets (Fig. 3). Treatment of B6 cells
with 200 WM EDHB for 12 h stimulates the expression of TfR
(lane 2, upper panel), and leads to a marked reduction in
ferritin steady-state levels (lane 2, middle panel). As expected,
similar results are obtained when the cells are treated with
100 WM DFO for 12 h (lane 3). The chelator treatments
Table 1
A⁄nity constants of chelators for Fe3þ
Chelator KD pMa
EDHBb 1.86U10327 M3 23.7
EDTAc 5.00U10323 M 25.3
DFOc 2.51U10326 M 28.6
a3log [Fe3þ] in the presence of 1 WM Fe3þ and 1 mM ligand at pH
7.4.
bMeasured in phosphate-bu¡ered saline (pH 7.4); the experiment
was performed twice and no signi¢cant variation in the values was
observed.
cValues from Critical Stability Constants (1977), Plenum Press, New
York.
Fig. 1. Activation of IRP1 by EDHB. B6 cells (6U106) were left
untreated (lane 1), or treated for 12 h with the indicated concentra-
tions of EDHB (lanes 2^4) or DFO (lane 5). Cytoplasmic extracts
(15 Wg) were analyzed by EMSA with 25 000 cpm 32P-labeled IRE
probe in the absence (top panel) or presence of 2% 2-mercaptoetha-
nol (2-ME) (bottom panel). The positions of the IRE/IRP1 com-
plexes and of excess free IRE probe are indicated by arrows. These
results are representative of those obtained from three experiments.
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have no e¡ect on the expression of L-actin, which serves as an
internal control (bottom panel).
4. Discussion
We show here that the prolyl 4-hydroxylase inhibitor
EDHB is a functional iron chelator. Its a⁄nity for Fe(III) is
substantially lower than that of DFO (Table 1). Nevertheless,
when applied to cultured cells, EDHB is capable of promoting
e¡ective iron de¢ciency. Moreover, the cellular responses to
the EDHB treatment examined here closely resemble the re-
sponses elicited by DFO. First, exposure of cells to micro-
molar concentrations of both EDHB and DFO trigger the
activation of IRP1 (Fig. 1). Second, as with DFO, the activa-
tion of IRP1 by EDHB is relatively slow and requires treat-
ment with the drug for at least 4 h (Fig. 2). Finally, both
EDHB and DFO modulate the coordinate expression of
downstream IRP1 targets, such as TfR and ferritin (Fig. 3).
It should be noted that another weak iron chelator, the tri-
dentate N-(2-hydroxybenzyl)-L-serine, with V108 times lower
KD compared to DFO, was recently found to activate IRP
with no appreciable e¡ect on HIF-1 [20].
Activated IRP binds to multiple IREs in the 3P-untranslated
region of TfR mRNA protects it against degradation, whereas
IRP binding to a single IRE in the 5P untranslated region of
ferritin mRNA inhibits its translation [17,18]. Surprisingly,
the inhibitory e¡ect of EDHB on ferritin expression appears
to be stronger than that of DFO (Fig. 3, middle panel), at
least under the experimental conditions tested (treatment with
the drugs for 12 h). The reason for this is unclear, but it may
be related to di¡erences in cell permeability between the two
drugs. Nevertheless, we have observed in the past that an
overnight (V16 h) treatment of B6 cells with 100 WM DFO
almost completely abolishes cellular ferritin content [21]. We
conclude that the iron chelating capacity of EDHB is su⁄-
cient to modulate the IRE/IRP regulatory system and to pro-
mote cellular responses to iron starvation. Importantly, the
time scale of these e¡ects is well within the time scale of
experiments in which EDHB has been employed to inhibit
collagen synthesis (it ranges from a few hours up to several
days [9^14]).
Our data suggest that EDHB is not as speci¢c an inhibitor
for prolyl 4-hydroxylases as previously thought. Moreover, its
capacity to perturb cellular iron metabolism could potentially
be associated with various pleiotropic e¡ects. Therefore, many
data obtained using this inhibitor should be interpreted with
Fig. 2. Time-dependent activation of IRP1 by EDHB and DFO. B6 cells (6U106) were left untreated (lanes 1 and 8), or exposed for the indi-
cated time periods to 100 WM DFO (lanes 2^7) or 200 WM EDHB (lanes 9^14). Cytoplasmic extracts (15 Wg) were analyzed by EMSA with
25 000 cpm 32P-labeled IRE probe in the absence (top panel) or presence of 2% 2-mercaptoethanol (2-ME) (bottom panel). The positions of
the IRE/IRP1 complexes and of excess free IRE probe are indicated by arrows. These results are representative of those obtained from three
experiments.
Fig. 3. Reciprocal e¡ects of EDHB in the expression of TfR and
ferritin. B6 cells (6U106) were left untreated (lane 1), or treated
with 200 WM EDHB or 100 WM DFO for 12 h. Cell extracts were
analyzed by Western blotting with antibodies against TfR (top), fer-
ritin (middle) or L2-actin (bottom). These results are representative
of those obtained from three experiments.
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caution. Along these lines, any strategies for the clinical ap-
plication of EDHB for the treatment of ¢brotic diseases
should take into account the function of the drug as an iron
chelator.
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